Radiation exposure, systemic manifestations, treatment and diet

Systemic lupus erythematosus (SLE) constitutes a complex, chronic autoimmune disorder characterized by systemic inflammation arising from dysregulated immune responses targeting the body’s own connective tissues. While patients with SLE consistently exhibit a broad array of autoantibodies—including antinuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA), anti-Smith (anti-Sm), and antiphospholipid antibodies—none of these markers demonstrate absolute specificity for the disease, thereby complicating definitive serological diagnosis. A pivotal observational milestone in unraveling the immunopathogenesis of SLE was the phenomenon of false-positive results in nontreponemal syphilis tests (e.g., VDRL), attributable to cross-reactivity between anticardiolipin antibodies and the lipid antigens employed in these assays. Persistence of such false-positive reactions for a minimum of six months may serve as a clinically significant indicator suggestive of SLE. Despite advances in identifying risk factors (genetic, environmental, hormonal) and elucidating the inflammatory cascade leading to organ damage, the etiopathogenesis of SLE remains incompletely understood. Contemporary medicine continues to seek answers to fundamental questions regarding the initiation of the disease process and its primary molecular and cellular underpinnings.

Systemic lupus erythematosus (SLE) demonstrates a pronounced gender disparity, affecting women at a frequency six to ten times higher than men. The clinical presentation of this condition may manifest in a localized manner, confined to a single organ or system, but it frequently adopts a generalized form that permeates multiple bodily systems. Among the most prevalent nonspecific symptoms are: diminished physical endurance, pronounced fatigue even with minimal exertion, and progressive, unexplained weight loss. The heterogeneity of clinical features is closely tied to the anatomical sites of inflammatory pathological alterations and the severity of the underlying autoimmune process, necessitating a tailored diagnostic and therapeutic approach for each individual case.

This intricate autoimmune disorder presents with cutaneous manifestations often localized to the face in a butterfly-shaped distribution, extending to the forehead, cheeks, scalp, or ear lobes, with exacerbations triggered by ultraviolet exposure. Less distinctive dermatological features may include patchy alopecia, lichen planus-like eruptions, pustular rashes, or Raynaud’s phenomenon—characterized by paroxysmal pallor, cyanosis, and rubor of the fingers, toes, nose, or ears. Systemic involvement encompasses musculoskeletal complaints (arthralgias, non-erosive arthritis, or myositis without structural joint damage), renal pathology (glomerulonephritis, nephrotic syndrome, acute kidney injury secondary to immune complex deposition), pulmonary manifestations (pleuritis, pulmonary hypertension), cardiovascular complications (pericarditis, myocarditis, arterial hypertension, accelerated atherosclerosis), and neurological sequelae (ischemic or hemorrhagic strokes, depressive episodes). Diagnostic confirmation mandates fulfillment of at least four of eleven classification criteria, including the presence of antinuclear antibodies (ANA), detectable in over 95% of patients, though their specificity is limited due to potential association with other conditions. The discussion further highlights clinical cases wherein lupus symptomatology mimicked HIV infection, emphasizing the diagnostic complexities inherent to this multisystem disease.

Glycocorticosteroids (GCS) are hormones produced naturally by the adrenal cortex. They have anti-inflammatory and immunosuppressive effects. When combined with the appropriate receptor, however, they affect some of the genes responsible for the production of pro inflammatory substances. Therefore, these drugs reduce inflammation while also weakening the body's resistance to osteoporosis (the activity of the tissues of the T cells).

The diet of a person suffering from rheumatoid arthritis should certainly be a balanced diet in accordance with the current Dietary Pyramid. However, if the balance of glucose in the liver is to be maintained, it should be taken into account in particular the condition of the individual systems and organs and the medicinal products used. When using GCS, care must be taken to ensure that only products with a low or medium glycemic index appear in the diet.